Build Your Comparison

Side-by-side financial analysis
NYXH logo
NYXH
LLY logo
LLY
KO logo
KO
Try popular comparisons:

Stock Comparison

NYXH vs LLY vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NYXH
Nyxoah S.A.

Medical - Instruments & Supplies

HealthcareNASDAQ • BE
Market Cap$52M
5Y Perf.-94.2%
LLY
Eli Lilly and Company

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1.07T
5Y Perf.+519.9%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+53.1%

NYXH vs LLY vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NYXH logoNYXH
LLY logoLLY
KO logoKO
IndustryMedical - Instruments & SuppliesDrug Manufacturers - GeneralBeverages - Non-Alcoholic
Market Cap$52M$1.07T$355.61B
Revenue (TTM)$16M$72.25B$49.28B
Net Income (TTM)$-86M$25.27B$13.70B
Gross Margin48.3%83.5%61.7%
Operating Margin-5.3%45.9%29.3%
Forward P/E30.9x25.3x
Total Debt$42M$42.50B$45.49B
Cash & Equiv.$30M$7.16B$10.27B

NYXH vs LLY vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NYXH
LLY
KO
StockApr 21Jun 26Return
Nyxoah S.A. (NYXH)1005.8-94.2%
Eli Lilly and Compa… (LLY)100619.9+519.9%
The Coca-Cola Compa… (KO)100153.1+53.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: NYXH vs LLY vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LLY leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. The Coca-Cola Company is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇LLY emerged as the overall leader. Track its performance:
NYXH
Nyxoah S.A.
The Growth Play

NYXH is the clearest fit if your priority is growth exposure.

  • Rev growth 121.6%, EPS growth -30.9%, 3Y rev CAGR 48.1%
  • 121.6% revenue growth vs KO's 1.9%
Best for: growth exposure
LLY
Eli Lilly and Company
The Long-Run Compounder

LLY carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 14.8% 10Y total return vs KO's 121.1%
  • Lower volatility, beta 0.53, current ratio 1.58x
  • PEG 1.07 vs KO's 2.26
Best for: long-term compounding and sleep-well-at-night
KO
The Coca-Cola Company
The Income Pick

KO is the clearest fit if your priority is income & stability.

  • Dividend streak 56 yrs, beta -0.20, yield 2.5%
  • Better valuation composite
  • 2.5% yield, 56-year raise streak, vs LLY's 0.5%, (1 stock pays no dividend)
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthNYXH logoNYXH121.6% revenue growth vs KO's 1.9%
ValueKO logoKOBetter valuation composite
Quality / MarginsLLY logoLLY35.0% margin vs NYXH's -5.3%
Stability / SafetyLLY logoLLYBeta 0.53 vs NYXH's 2.10
DividendsKO logoKO2.5% yield, 56-year raise streak, vs LLY's 0.5%, (1 stock pays no dividend)
Momentum (1Y)LLY logoLLY+40.3% vs NYXH's -81.6%
Efficiency (ROA)LLY logoLLY22.7% ROA vs NYXH's -80.8%, ROIC 41.8% vs -76.4%

NYXH vs LLY vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NYXHNyxoah S.A.

Segment breakdown not available.

LLYEli Lilly and Company
FY 2025
Product
93.5%$61.0B
Collaboration and Other Revenue
6.5%$4.2B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

NYXH vs LLY vs KO — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLLYLAGGINGNYXH

Income & Cash Flow (Last 12 Months)

LLY leads this category, winning 4 of 6 comparable metrics.

LLY is the larger business by revenue, generating $72.2B annually — 4427.6x NYXH's $16M. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to NYXH's -5.3%. On growth, NYXH holds the edge at +5.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNYXH logoNYXHNyxoah S.A.LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$16M$72.2B$49.3B
EBITDAEarnings before interest/tax-$81M$34.7B$15.5B
Net IncomeAfter-tax profit-$86M$25.3B$13.7B
Free Cash FlowCash after capex-$73M$13.6B$12.6B
Gross MarginGross profit ÷ Revenue+48.3%+83.5%+61.7%
Operating MarginEBIT ÷ Revenue-5.3%+45.9%+29.3%
Net MarginNet income ÷ Revenue-5.3%+35.0%+27.8%
FCF MarginFCF ÷ Revenue-4.5%+18.8%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+5.9%+55.5%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+38.3%+169.9%+18.2%
LLY leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — NYXH and KO each lead in 3 of 7 comparable metrics.

At 27.2x trailing earnings, KO trades at a 45% valuation discount to LLY's 49.4x P/E. Adjusting for growth (PEG ratio), LLY offers better value at 1.71x vs KO's 2.43x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNYXH logoNYXHNyxoah S.A.LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…
Market CapShares × price$52M$1.07T$355.6B
Enterprise ValueMkt cap + debt − cash$66M$1.11T$390.8B
Trailing P/EPrice ÷ TTM EPS-0.51x49.37x27.18x
Forward P/EPrice ÷ next-FY EPS est.30.95x25.27x
PEG RatioP/E ÷ EPS growth rate1.71x2.43x
EV / EBITDAEnterprise value multiple35.38x26.39x
Price / SalesMarket cap ÷ Revenue4.48x16.42x7.42x
Price / BookPrice ÷ Book value/share0.93x38.34x10.40x
Price / FCFMarket cap ÷ FCF119.31x67.15x
Evenly matched — NYXH and KO each lead in 3 of 7 comparable metrics.

Profitability & Efficiency

LLY leads this category, winning 6 of 9 comparable metrics.

LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $-164 for NYXH. NYXH carries lower financial leverage with a 0.86x debt-to-equity ratio, signaling a more conservative balance sheet compared to LLY's 1.60x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs NYXH's 2/9, reflecting strong financial health.

MetricNYXH logoNYXHNyxoah S.A.LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-164.4%+101.2%+41.1%
ROA (TTM)Return on assets-80.8%+22.7%+13.1%
ROICReturn on invested capital-76.4%+41.8%+15.8%
ROCEReturn on capital employed-80.4%+46.6%+17.3%
Piotroski ScoreFundamental quality 0–9287
Debt / EquityFinancial leverage0.86x1.60x1.33x
Net DebtTotal debt minus cash$12M$35.3B$35.2B
Cash & Equiv.Liquid assets$30M$7.2B$10.3B
Total DebtShort + long-term debt$42M$42.5B$45.5B
Interest CoverageEBIT ÷ Interest expense-32.73x35.68x10.70x
LLY leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LLY leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in LLY five years ago would be worth $51,207 today (with dividends reinvested), compared to $515 for NYXH. Over the past 12 months, LLY leads with a +40.3% total return vs NYXH's -81.6%. The 3-year compound annual growth rate (CAGR) favors LLY at 37.2% vs NYXH's -44.0% — a key indicator of consistent wealth creation.

MetricNYXH logoNYXHNyxoah S.A.LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-69.1%+5.2%+20.3%
1-Year ReturnPast 12 months-81.6%+40.3%+17.2%
3-Year ReturnCumulative with dividends-82.4%+158.2%+47.0%
5-Year ReturnCumulative with dividends-94.9%+412.1%+65.6%
10-Year ReturnCumulative with dividends-94.2%+1484.6%+121.1%
CAGR (3Y)Annualised 3-year return-44.0%+37.2%+13.7%
LLY leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than NYXH's 2.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs NYXH's 16.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNYXH logoNYXHNyxoah S.A.LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5002.10x0.53x-0.20x
52-Week HighHighest price in past year$8.59$1182.73$84.04
52-Week LowLowest price in past year$1.26$623.78$65.35
% of 52W HighCurrent price vs 52-week peak+16.2%+95.8%+98.3%
RSI (14)Momentum oscillator 0–10025.870.060.6
Avg Volume (50D)Average daily shares traded189K2.6M12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: NYXH as "Buy", LLY as "Buy", KO as "Buy". Consensus price targets imply 331.7% upside for NYXH (target: $6) vs 4.2% for KO (target: $86). For income investors, KO offers the higher dividend yield at 2.46% vs LLY's 0.53%.

MetricNYXH logoNYXHNyxoah S.A.LLY logoLLYEli Lilly and Com…KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$6.00$1268.94$86.13
# AnalystsCovering analysts54548
Dividend YieldAnnual dividend ÷ price+0.5%+2.5%
Dividend StreakConsecutive years of raises1156
Dividend / ShareAnnual DPS$6.00$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.4%+0.2%
KO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

LLY leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KO leads in 2 (Risk & Volatility, Analyst Outlook). 1 tied.

Best OverallEli Lilly and Company (LLY)Leads 3 of 6 categories
Loading custom metrics...

NYXH vs LLY vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NYXH or LLY or KO a better buy right now?

For growth investors, Nyxoah S.

A. (NYXH) is the stronger pick with 121. 6% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Nyxoah S. A. (NYXH) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NYXH or LLY or KO?

On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.

2x versus Eli Lilly and Company at 49. 4x. On forward P/E, The Coca-Cola Company is actually cheaper at 25. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 1. 07x versus The Coca-Cola Company's 2. 26x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — NYXH or LLY or KO?

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -94. 9% for Nyxoah S. A. (NYXH). Over 10 years, the gap is even starker: LLY returned +1485% versus NYXH's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NYXH or LLY or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Nyxoah S. A. 's 2. 10β — meaning NYXH is approximately -1147% more volatile than KO relative to the S&P 500. On balance sheet safety, Nyxoah S. A. (NYXH) carries a lower debt/equity ratio of 86% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — NYXH or LLY or KO?

By revenue growth (latest reported year), Nyxoah S.

A. (NYXH) is pulling ahead at 121. 6% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -30. 9% for Nyxoah S. A.. Over a 3-year CAGR, NYXH leads at 48. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NYXH or LLY or KO?

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -899. 1% for Nyxoah S. A. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -827. 8% for NYXH. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NYXH or LLY or KO more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 1. 07x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, The Coca-Cola Company (KO) trades at 25. 3x forward P/E versus 30. 9x for Eli Lilly and Company — 5. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NYXH: 331. 7% to $6. 00.

08

Which pays a better dividend — NYXH or LLY or KO?

In this comparison, KO (2.

5% yield), LLY (0. 5% yield) pay a dividend. NYXH does not pay a meaningful dividend and should not be held primarily for income.

09

Is NYXH or LLY or KO better for a retirement portfolio?

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Nyxoah S. A. (NYXH) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, NYXH: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NYXH and LLY and KO?

These companies operate in different sectors (NYXH (Healthcare) and LLY (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NYXH is a small-cap high-growth stock; LLY is a mega-cap high-growth stock; KO is a large-cap quality compounder stock. LLY, KO pay a dividend while NYXH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.